Full text
Earnings transcript
Read the complete earnings call transcript.
REGN
Regeneron Pharmaceuticals, Inc.
$761.85
-15.4
(-1.98%)
| Exchange: | NASDAQ |
| Market Cap: | 79.158B |
| Shares Outstanding: | 15.364M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Leonard S. Schleifer | |||||
| Full Time Employees: | 15158 | |||||
| Address: |
| |||||
| Website: | https://www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 13,117,200 | 14,202,000 | 14,342,900 |
| Gross Profit | 10,872,700 | 12,231,500 | 12,242,200 |
| EBITDA | 4,693,300 | 5,318,000 | 5,818,200 |
| Operating Income | 4,348,600 | 3,990,700 | 3,577,900 |
| Net Income | 3,953,600 | 4,412,600 | 4,504,900 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 33,080,200 | 37,759,400 | 40,558,700 |
| Total Liabilities | 7,107,100 | 8,405,800 | 2,747,600 |
| Total Stockholders Equity | 25,973,100 | 29,353,600 | 31,256,900 |
| Total Debt | 2,702,900 | 2,704,400 | 2,705,900 |
| Cash and Cash Equivalents | 2,730,000 | 2,488,200 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 4,594,000 | 4,420,500 | 4,978,900 |
| Capital Expenditure | -926,400 | -755,900 | -898,400 |
| Free Cash Flow | 3,667,600 | 3,664,600 | 4,080,500 |
| Net Income | 3,953,600 | 4,412,600 | 4,504,900 |
| Net Change in Cash | -381,600 | -248,800 | 634,700 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 19,642,315.875 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 23,457,649.148 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 21,440,521.929 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 8,531,096.118 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 10,188,180.500 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 9,312,097.135 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 6,984,777.394 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 8,798,330.079 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 7,839,523.476 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 3,446,213.708 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 4,115,607.985 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 3,761,706.158 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 72.190 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 81.020 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 64.320 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 11 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 6 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: REGN demonstrates strong revenue and net income growth as reflected in recent income statements, underpinned by consistent operating cash flow and free cash flow generation. The freeCashFlowYieldTTM indicates a solid return on investment for shareholders.
- High Profitability Metrics: The company exhibits impressive grossProfitMarginTTM and netProfitMarginTTM, showcasing operational efficiency and a competitive edge within the biotechnology industry.
- Strong Balance Sheet: REGN maintains a healthy currentRatioTTM and quickRatioTTM, indicating good liquidity to cover short-term obligations. Additionally, a low debtToEquityRatioTTM reflects a conservative approach to leverage, reducing financial risk.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates REGN intrinsic value between $468.48 – $770.39 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about REGN valuation
Is Regeneron Pharmaceuticals, Inc. (REGN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Regeneron Pharmaceuticals, Inc. (REGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is REGN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether REGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is REGN’s P/E ratio?
You can see REGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for REGN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is REGN a good long-term investment?
Whether REGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
REGN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
-1.98
Trading Metrics:
| Open: | 767.23 | Previous Close: | 777.25 | |
| Day Low: | 745 | Day High: | 770.11 | |
| Year Low: | 476.49 | Year High: | 821.11 | |
| Price Avg 50: | 765.5 | Price Avg 200: | 662.72 | |
| Volume: | 1M | Average Volume: | 732303 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeREGN full analysis
Welcome to MARKETSNAP’s SWOT analysis for Regeneron Pharmaceuticals, a heavyweight in the biotech space that many of you are likely already familiar with. If you’re invested in the health sector or just keeping an eye on innovative companies, you’ve probably heard of Regeneron, or REGN on the ticker. Today, we’re diving deep into what makes this company tick, breaking down its strengths, weaknesses, opportunities, and threats, all while keeping a long-term investor’s perspective in mind. Let’s unpack the latest developments,…
